Insilico Partners to Build AI Longevity Model

Insilico Medicine, an AI drug discovery company based in Hong Kong, is advancing its efforts to utilize artificial intelligence for the purpose of extending human lifespan. The firm has established a partnership with a US-based entity to collaborate on the development of an AI model specifically designed to target human longevity. This initiative represents a significant step in applying advanced AI technologies to the complex field of aging research and therapeutic development, aiming to unlock new possibilities for healthier, longer lives.